CANARX Official Arrested in US Drug Importation Case as FDA Scrutiny Deepens

CANARX Official Arrested over alleged illegal prescription drug imports in the US. The case raises fresh questions about drug safety and FDA oversight.

A Senior CANARX official arrested in the United States over allegations of illegally importing prescription medicines, bringing renewed scrutiny to the Canadian healthcare company's operations. John Thomas Howard, CANARX's treasurer and a board director, was arrested Sunday on federal smuggling and conspiracy charges.

According to CNBC, court documents filed on November 10 indicate that Howard has also been charged for involvement in criminal activities through the importation and distribution of misbranded medications in the interstate market. Bob Howard, who is a director and the president of CANARX, is also being sought by federal investigators but he remains at large. No pleadings have been made by anyone.

How did a healthcare cost-saving business become the subject of a federal investigation?

Founded in 2002, CANARX operates out of Windsor, Ontario, using alternative funding programs (AFP). The latter helps employers reduce costs associated with the prescriptions by shipping medicine from other countries to the US customers.

Nonetheless, FDA had some reservations concerning such methods. As it is written in the affidavit by FDA special agent Dustin Dobbs, during the investigation, the investigators found probable cause to believe that CANARX illegally shipped prescription drugs into the country. The criminal complaint includes activity dates ranging from February 2017 to April 2026.

In addition, the company was regulated previously. Indeed, in 2019, FDA issued a warning letter to CANARX, and in 2023, it seized medicine shipments due to misbranded and counterfeit drugs.

Are lower drug prices worth the regulatory risks?

CANARX general counsel Joseph Morris rejected the allegations in a statement.

"The Howards deny all the charges against them, will defend vigorously, and expect to be vindicated in court," Morris said.

This is in addition to a private civil action suit brought against CANARX and others for illegal imports of Biktarvy, an HIV therapy, by the company Gilead Sciences.

A Gilead spokesperson stated that the company "has taken strong legal action to protect patients and the integrity of the U.S. medicines supply chain."

Could this case change how alternative funding programs operate?

Business Honor observes that the CANARX drug importation case exposes a difficult conflict in the US healthcare system. The employers wish for reduced drug prices; however, the overseas procurement policy is likely to face issues regarding regulatory approvals and safety issues. The lawsuit will establish the veracity of these allegations. For the pharmaceutical sector at large, this can have implications for alternative sources of funding and overseas procurement of medicines.

FAQs

Why was the CANARX official arrested?

John Thomas Howard was arrested on federal charges involving alleged prescription drug smuggling, conspiracy and illegal drug importation.

Who is John Thomas Howard?

John Thomas Howard is CANARX's treasurer and a director. He was arrested in connection with the federal drug importation investigation.

What is the CANARX drug importation case about?

The case involves allegations that CANARX illegally imported prescription medicines into the United States through overseas supply channels.

Is CANARX president Bob Howard also arrested?

No. Bob Howard is wanted in the federal investigation but had not been taken into custody in the reported coverage.

What is the FDA's role in the CANARX investigation?

The FDA's Office of Criminal Investigations is involved in examining alleged illegal drug imports and potential violations involving prescription medicines.